Federal contractor profile

ADJUVAX LLC

UEI EGVNJG3GMEL7CAGE 8RK88Company website ↗

Active
Small Business

Overview

Legal name
ADJUVAX LLC
Registered location
HOOVER, AL, USA
Website
Company website ↗
Primary NAICS
541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Latest award activity
Apr 15, 2025
Read company summary

ADJUVAX LLC is associated with UEI EGVNJG3GMEL7 and CAGE 8RK88 in public federal records. AcornBids currently links 1 prime award totaling $3.0M in obligations to this entity. Its largest recorded federal customer by obligations is Department of Health and Human Services. Its recorded federal awards include work classified as Research and Development in Biotechnology (except Nanobiotechnology). These categories describe the loaded award records, not a complete list of company capabilities. Its primary SAM.gov NAICS is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)). Its public SAM.gov registration lists HOOVER, AL, USA.

At a glance

Lifetime prime obligations$3.0M
Prime awards1
Awards with future end dates0
Top-agency concentration100.0%

Prime contract obligations across loaded award records. Obligations are not revenue or contract ceilings. Summary updated Oct 11, 2026. Refresh pending; these totals may be out of date.

Business information

Public SAM.gov registration details.

Legal name
ADJUVAX LLC
UEI
EGVNJG3GMEL7
CAGE
8RK88
Registered address
622 RENAISSANCE DR, HOOVER, AL, 35226, USA
Registration status
Active
Primary NAICS
541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM activation
Jan 20, 2026
Initial registration
Oct 7, 2020
Entity start
Apr 16, 2020
SAM updated
Jan 20, 2026
Registration expires
Jan 16, 2027
Fiscal year end
Apr 15
Place of incorporation
AL, USA

View SAM.gov source

Research brief

Source facts

  • Loaded prime-award records link 1 awards and $3,000,000 in reported obligations to this legal entity. Source
  • Recorded awards include Research and Development in Biotechnology (except Nanobiotechnology) (NAICS 541714); this classification is not proof of every company capability. Source
  • An example award describes: SBIR BASE YEAR - TOPIC 130 ADJUVANT DISCOVERY AND DOWN-SELECTION FOR VACCINES AGAINST INFECTIOUS AND IMMUNE-MEDIATED DISEASES Source

Federal award analysis

Net transaction obligations by federal fiscal period.

Selected transaction obligations$3.0M
Prime contracts

Reported transaction obligations by federal fiscal period; includes deobligations. Missing transactions are not estimated. Coverage: 1 of 1 selected awards. Select a period to explore its awards.

Funding change

Dated, valued transaction obligations in equal-length adjacent periods; missing records are unknown. Default: last completed federal fiscal year. Percentage is unavailable when the prior period has no positive reported obligations.

MeasureReported value
Current periodOct 1, 2025 – Sep 30, 2026
Current obligationsNot reported
Prior periodOct 1, 2024 – Sep 30, 2025
Prior obligations$3.0M
ChangeNot reported
GrowthNot comparable

Where the work is performed

AKMEVTNHWAIDMTNDMNWIMINYMAORNVWYSDIAILINOHPANJCTRICAUTCONEMOKYWVVAMDDEAZNMKSARTNNCSCDCOKLAMSALGAHITXFL

State tile map; darker tiles have larger absolute net obligations. Outlined tiles indicate net deobligations. Unshaded tiles have no reported transactions in this selection. Other locations appear in the table.

Agencies
CategoryPeriod obligationsAwards
Department of Health and Human Services$3.0M1
Offices
CategoryPeriod obligationsAwards
NATIONAL INSTITUTES OF HEALTH NIAID$3.0M1
Naics
Psc
Vehicles
CategoryPeriod obligationsAwards
Unclassified$3.0M1
States
CategoryPeriod obligationsAwards
AL$3.0M1
Set Asides
CategoryPeriod obligationsAwards
SMALL BUSINESS SET ASIDE - TOTAL$3.0M1

Recent federal awards

Prime contract awards. Select an award to review its history and source evidence.

Award / descriptionAwarding agencyObligationsStart dateEnd date
75N93025C00007SBIR BASE YEAR - TOPIC 130 ADJUVANT DISCOVERY AND DOWN-SELECTION FOR VACCINES AGAINST INFECTIOUS AND IMMUNE-MEDIATED DISEASESDepartment of Health and Human Services$3.0MNov 1, 2024Apr 15, 2025

Upcoming positioning windows

Modeled recompete windows are estimates, not announced solicitations or guarantees.

Registration, certifications & contacts

Registration evidenceDate
SAM updatedJan 20, 2026
Source loadedSep 2, 2026
Initial registrationOct 7, 2020
Entity startApr 16, 2020

Registration classifications: Self Certified Small Disadvantaged Business, Small Business. These are separate from the reported certificates above.

IndustryReported size status
541714 — Research and Development in Biotechnology (except Nanobiotechnology)Not reported
541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)Not reported
ContactRolePublished contact methodsEvidenceSource date
WEIWEI LIGovernment businessContact method not publishedSAM registrationNot available
WEIWEI LIElectronic businessContact method not publishedSAM registrationNot available
Registered industries
  • 541714 — Research and Development in Biotechnology (except Nanobiotechnology)
  • 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Registration classifications and published certificates do not by themselves establish eligibility for a particular solicitation. View SAM source

Related companies worth researching

Explore the customer, work and award-size evidence behind each match.

MASSACHUSETTS INSTITUTE OF TECHNOLOGY

1 shared agency customer(s); Shared work: 541714 — Research and Development in Biotechnology (except Nanobiotechnology); Average reported award size within 0.5–2× in matching records. Counts and amounts describe sampled matching awards, not the company’s full history.
1 awards

GLAXOSMITHKLINE, LLC

1 shared agency customer(s); Shared work: 541714 — Research and Development in Biotechnology (except Nanobiotechnology); Average reported award size within 0.5–2× in matching records. Counts and amounts describe sampled matching awards, not the company’s full history.
15 awards

THE JOHNS HOPKINS UNIVERSITY

1 shared agency customer(s); Shared work: 541714 — Research and Development in Biotechnology (except Nanobiotechnology); Average reported award size within 0.5–2× in matching records. Counts and amounts describe sampled matching awards, not the company’s full history.
4 awards

GODX INC

1 shared agency customer(s); Shared work: 541714 — Research and Development in Biotechnology (except Nanobiotechnology); Average reported award size within 0.5–2× in matching records. Counts and amounts describe sampled matching awards, not the company’s full history.
1 awards

UNIVERSITY OF SOUTHERN CALIFORNIA

1 shared agency customer(s); Shared work: 541714 — Research and Development in Biotechnology (except Nanobiotechnology); Average reported award size within 0.5–2× in matching records. Counts and amounts describe sampled matching awards, not the company’s full history.
1 awards

SPAULDING CLINICAL RESEARCH, LLC

1 shared agency customer(s); Shared work: 541714 — Research and Development in Biotechnology (except Nanobiotechnology); Average reported award size within 0.5–2× in matching records. Counts and amounts describe sampled matching awards, not the company’s full history.
1 awards
Data coverage and methodology

Sources: SAM.gov registration, USAspending awards and transactions, and linked supporting records. Prime contract obligations, IDV ceilings and assistance amounts are kept separate. Missing records are not zero activity. Company claims are labeled separately. Recompete signals are rule-based scores out of 100. Positioning windows are AcornBids estimates.

Disclosed relationships only. Missing records do not establish that a contractor has no partners. Ambiguous parent award identifiers are excluded.

Keep your research moving

Save this company, track changes, and evaluate upcoming work against your targets.

Save to my research Find my fit